WINDTREE THERAPEUTICS INC
NASDAQ: WINT (Windtree Therapeutics, Inc.)
Kemas kini terakhir: 1 jam lalu0.000
0.00 (0.00%)
| Purata Dagangan (3B) | 58,768 |
| Modal Pasaran | 3,370 |
| Harga / Pendapatan (P/E TTM) | 0.000 |
| Harga / Pendapatan (P/E Ke hadapan) | 0.370 |
| Harga / Jualan (P/S) | 660.53 |
| Harga / Buku (P/B) | 0.610 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -6,321.50 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 15.34% |
| Nisbah Semasa (MRQ) | 0.250 |
| Aliran Tunai Operasi (OCF TTM) | -14.86 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -13.41 M |
| Pulangan Atas Aset (ROA TTM) | -53.20% |
| Pulangan Atas Ekuiti (ROE TTM) | -124.86% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Windtree Therapeutics, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -1.0 |
| Purata | -0.17 |
|
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.01% |
| % Dimiliki oleh Institusi | 1.39% |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |